See how AbbVie Inc. and NVIDIA Corporation differ across market data and performance, so you can decide which asset best fits your strategy.
$254.49
NYSE
AbbVie Inc. is a pharmaceutical company with significant exposure to immunology through Humira, Skyrizi, and Rinvoq, and to oncology through Imbruvica and Venclexta. The company was spun off from Abbott in early 2013. Its 2020 acquisition of Allergan expanded its portfolio with additional products in aesthetics, including Botox. In 2024, AbbVie further strengthened its business through the acquisitions of Cerevel in neuroscience and ImmunoGen in oncology.
NVIDIA is a leading designer of graphics processing units (GPUs). Historically, GPUs were used to improve performance and user experience across computing platforms, especially in PC gaming. Over time, GPUs have become essential semiconductors for artificial intelligence, powering large language models and other advanced AI workloads. In addition to AI-focused GPUs, NVIDIA provides its CUDA software platform, which supports AI model development and training. The company is also expanding its data center networking solutions, helping connect GPUs to manage increasingly complex workloads.